Canopy Growth Corp vs InMode Ltd — how do they compare? Canopy Growth Corp trades at $0.98 (market cap $398.46M), while InMode Ltd trades at $15.07 (market cap $857.04M). The key difference: InMode Ltd is far larger — about 2.2× Canopy Growth Corp's market cap, and InMode Ltd is trading nearer its 52-week high, Canopy Growth Corp nearer its low. Which is the better fit depends on your goals.
| CGC | INMD | |
|---|---|---|
Market Cap | $398.46M | $857.04M |
Sector | Health | Technology |
52-Week High | $1.92 | $16.62 |
52-Week Low | $0.86 | $12.76 |
Enterprise Value | $337.90M | $324.71M |
Signals from Pluang's Aura AI — not financial advice
Canopy Growth (CGC) trades at $0.96, down 1.15% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported a net loss of $598.12 million in 2025, with revenue declining to $269 million, though recent quarterly earnings showed one beat and two misses against expectations. Cash flow remains negative, but the balance sheet shows improving debt-to-asset ratios, down to 33.13% in 2025 from 53.61% in 2023.
The outlook is cautious; while cost-cutting and restructuring efforts are underway, profitability remains elusive, and the stock faces risks including potential delisting due to low share price. Analyst sentiment is divided, with 33% recommending buy, 41% hold, and 26% sell. Investors should weigh the potential for a turnaround against significant operational and regulatory challenges in the cannabis sector.
INMD trades at $15.15, down 0.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company maintains strong profitability with a 77.84% gross margin and a P/E of 11.04, indicating potential undervaluation. Recent news includes an unsolicited acquisition offer at $16.75 per share and upcoming Q2 2026 earnings on August 5, 2026, with revenue guidance of $95.2M-$95.4M.
The outlook is mixed: solid fundamentals and a takeover bid provide upside potential, but risks include earnings misses, legal investigations, and shareholder opposition to the acquisition. Analyst consensus is a $16.50 price target with a balanced buy/hold split, suggesting cautious optimism amid near-term volatility.
Trailing returns across standard periods
Latest headlines on both assets
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →